Gene panel | First author, year, Ref. No. | Country | Study group | No. | DNAm assay | OR (95% CI) | p-valuea | CRC stage | N | Stage-specific OR (95% CI) | p-valuea | p-valueb |
---|---|---|---|---|---|---|---|---|---|---|---|---|
MGMT, MLH1, and VIM (promoters) | Baek, 2009 [44] | South Korea | NAA AA Ad CRC Cn | 30 22 52 60 37 | MSP | 14.9 (4.4–50.8) 5.3 (1.5–18.8) 9.5 (3.2–28.2) 19.2 (6.3–58.2) | < 0.001 0.01 < 0.001 < 0.001 | I/II III/IV | 35 25 | 16.0 (4.9–52.8) 25.6 (6.6–99.7) | < 0.001 < 0.001 | 0.450 |
ITGA4, SFRP2, and CDKN2A (promoters) | Chang, 2010 [46] | Korea | NAA AA Ad CRC Cn | 17 8 25 30 31 | MSP | 55.0 (5.9–509.9) 210.0 (11.7–3783.8) 77.1 (8.8–679.2) 70.0 (8.2–594.9) | < 0.001 < 0.001 < 0.001 < 0.001 | I/II III/IV | 14 16 | 54.0 (5.6–524.0) 90.0 (9.1–889.9) | < 0.001 < 0.001 | 0.694d |
SFRP2, GATA4/5, NDRG4, and VIM (promoters) | Lu, 2014 [49] | China | CRC Cn | 56 40 | MSP | 50.1 (10.6–237.1) | < 0.001 | I/II III/IV | 32 24 | 27.9 (5.8–134.2) 89.6 (5.1–1583.0)c | < 0.001 < 0.001 | 0.501d |
SFRP2 and WIF-1 (promoters) | Zhang, 2014 [50] | China | NAA AA Ad CRC Cn | 20 15 35 48 30 | MSP | 35.4 (4.0–313.4) 116.0 (10.9–1229.9) 55.6 (6.7–459.5) 125.7 (15.1–1048.2) | < 0.001 < 0.001 < 0.001 < 0.001 | I/A II/B III/C IV/D | 7 20 14 7 | 174.0 (9.5–3187.4) 116.0 (11.9–1128.2) 72.5 (7.2–727.6) 295.0 (10.9–7994.2)c | < 0.001 < 0.001 < 0.001 < 0.001 | 0.605d |
SFRP2, TFPI2, NDRG4, and BMP3 (promoters) | Park, 2017 [34] | South Korea | AA CRC Cn | 36 35 40 | MSP | 3.2 (1.2–8.3) 20.2 (4.3–95.7) | 0.017 < 0.001 | I/II III/IV | 17 18 | 9.2 (1.9–45.5) 45.0 (2.5–798.2)c | 0.003 0.000 | 0.229d |
COL4A2 and TLX2 (promoter/exon 1) | Liu, 2019 [40] | China | AA CRC Cn | 77 80 83 | qMSP | 43.8 (10.0–190.9) 422.4 (85.0–2098.2) | < 0.001 < 0.001 | I/II III/IV | 43 37 | 249.8 (48.1–1296.4) 1458.0 (128.1–16,600.2) | < 0.001 < 0.001 | 0.168 |